To align with current clinical practice in melanoma management, we subsequently extended the BrafV600E inhibitor (Brafi)-resistant population and assessed the efficacy of senolytic therapy using CDK4/6i and GLS1i in Brafi vemurafenib-resistant BrafV600E melanoma cells. Here, CDK4 is linked to melanoma.